Acceleron Pharma reported $-18000000 in EBITDA for its second fiscal quarter of 2020.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Ebitda Change
Acceleron Pharma XLRN:US $ -18M 33M
Akebia Therapeutics AKBA:US $ -51.48M 2.8M
Alexion Pharmaceuticals ALXN:US $ 777.5M 44.6M
Amgen AMGN:US $ 3253M 1M
Bayer BAYN:GR € 2780M 1635M
Biomarin Pharmaceutical BMRN:US $ -16.91M 85.25M
Bluebird Bio BLUE:US $ -23.05M 178.6M
Clovis Oncology CLVS:US $ -81M 1M
Dicerna Pharmaceuticals DRNA:US $ -22.35M 10.61M
Eli Lilly And LLY:US $ 1763M 213.6M
Exelixis EXEL:US $ 77M 23M
Gilead Sciences GILD:US $ -2633M 5384M
GlaxoSmithKline GSK:LN 1750M 932M
Johnson & Johnson JNJ:US $ 8019M 2082M
Neurocrine Biosciences NBIX:US $ 124M 63M
Pfizer PFE:US $ 5103M 939M
Ptc Therapeutics PTCT:US $ -125.24M 41.48M
Puma Biotechnology PBYI:US $ 9M 22M
Regeneron Pharmaceuticals REGN:US $ 715.2M 41M
Ultragenyx Pharmaceutical RARE:US $ -59.87M 57.94M
United Therapeutics UTHR:US $ 153.1M 26M
Vertex Pharmaceuticals VRTX:US $ 753.93M 5.28M